ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Laser Photonics Advances Pill Drilling R&D to Increase Presence in Pharmaceutical Market

Modern Solutions for Manufacturing Time-Release Medication

Laser Photonics Corporation (NASDAQ: LASE) (“LPC”), a leading global developer of industrial laser systems for cleaning and other material processing applications, joined by its recently acquired subsidiary, Control Micro Systems, Inc. (CMS), announced today the expansion of its tablet laser drilling technology development program targeting the pharmaceutical and medical technology market.

Tablet laser drilling is a proven, economically viable way to create sub-millimeter apertures in pharmaceutical tablets. This method plays a key role in osmotic pump time-release drug delivery systems, which provide many health benefits like decreasing dosing frequencies, maintaining consistent drug levels in the body over a specific period and enabling customized delivery profiles.

The Tablet Laser Drilling technology by CMS provides an automated, high-speed process capable of drilling up to 140,000 tablets per hour with orifices as small as 200 microns. This technology is engineered to achieve precise dimensional tolerances for osmotic pump tablets and related drug delivery systems, making laser drilling the preferred method for modern pharmaceutical tablet production. Machine vision technology for visual inspection ensures quality and alignment, checking each tablet twice for hole position, size, and/or number before reaching the collection bin. Rejection of produced tablets is rare due to the precision of the system, and any failed tablets are speedily ejected into separate bins.

For LPC, established as a trusted provider of industrial laser equipment, pharmaceutical and medical technologies is a new sector of focus. Supplemented by CMS expertise, LPC is dedicating resources to research and development in this sector in accordance with its broad diversification strategy, poised to contribute to growing shareholder value and foster greater resilience in evolving markets.

“With the expansion of R&D and the integration of CMS expertise, we can rapidly advance our product offerings to meet the high demands of the pharmaceutical industry,” said Wayne Tupuola, CEO of LPC. “Our focus on precision and efficiency is transforming drug delivery systems, ensuring optimal performance and patient safety. We are committed to driving forward the future of pharmaceutical manufacturing with cutting-edge solutions that enhance patient outcomes and streamline production processes.”

For more information, visit the LPC website at www.laserphotonics.com.

About CMS Laser

Control Micro Systems (CMS Laser), is a 40-year U.S. pioneer in software controls development for laser machines. Today, the company produces turnkey laser material processing systems for marking, cutting, drilling, welding, and more. Its cutting-edge laser systems are expertly engineered for high-precision applications in a wide range of industries and tailored to each clients’ unique manufacturing needs. CMS Laser specializes in developing custom laser systems for a wide range of industries, including solutions for slow-release tablets and counterfeit-proof pill manufacturing. It also counts several top 20 global life sciences companies among their customers. For more information, visit CMS Laser, a Laser Photonics company.

About Laser Photonics Corporation

Laser Photonics is a vertically integrated manufacturer and R&D Center of Excellence for industrial laser technologies and systems. Laser Photonics seeks to disrupt the $46 billion, centuries-old sand and abrasives blasting markets, focusing on surface cleaning, rust removal, corrosion control, de-painting and other laser-based industrial applications. Laser Photonics’ new generation of leading-edge laser blasting technologies and equipment also addresses the numerous health, safety, environmental and regulatory issues associated with old methods. As a result, Laser Photonics quickly gained a reputation as an industry leader in industrial laser systems with a brand that stands for quality, technology and product innovation. Currently, world-renowned and Fortune 1000 manufacturers in the aerospace, automotive, defense, energy, maritime, nuclear and space industries are using Laser Photonics’ “unique-to-industry” systems. For more information, visit https://www.laserphotonics.com.

Cautionary Note Concerning Forward-Looking Statements

This press release contains “forward-looking statements” (within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended), including statements regarding the Company’s plans, prospects, potential results and use of proceeds. These statements are based on current expectations as of the date of this press release and involve a number of risks and uncertainties, which may cause results and uses of proceeds to differ materially from those indicated by these forward-looking statements. These risks include, without limitation, those described under the caption “Risk Factors” in the Registration Statement. Any reader of this press release is cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release except as required by applicable laws or regulations.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  228.43
+0.00 (0.00%)
AAPL  270.97
+0.00 (0.00%)
AMD  214.95
+0.00 (0.00%)
BAC  55.88
+0.00 (0.00%)
GOOG  311.33
+0.00 (0.00%)
META  661.50
+0.00 (0.00%)
MSFT  484.92
+0.00 (0.00%)
NVDA  183.60
-0.09 (-0.05%)
ORCL  198.38
+0.00 (0.00%)
TSLA  489.08
+0.35 (0.07%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.